Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
betamethasone valerate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1:1 | EXPERIMENTAL | Part 1 - eczema treatment |
| 1:2 | ACTIVE_COMPARATOR | Part 1 - eczema treatment |
| 2:1 | EXPERIMENTAL | Part 2 - maintenance treatment |
| 2:2 | NO_INTERVENTION | Part 2 - maintenance treatment |
| Name | Type | Description |
|---|---|---|
| betamethasone valerate | DRUG | Topical application according to a fixed schedule for three weeks |
| urea | DRUG | Topical application twice daily for up to 6 months |
Inclusion Criteria: * Females and males between 18 and 65 years of age * Caucasian * AD according to the criteria of Hanifin and Rajka (12) with eczematous lesions corresponding to an Atopic Dermatitis Severity Index (ADSI) (13) score of at least 6 on any of the following areas: arms, legs, chest, ...
Betamethasone valerate is a small molecule being studied for the treatment of atopic eczema, a form of dermatitis. It is a topical corticosteroid intended to reduce skin inflammation and irritation associated with the condition. The drug is currently in Phase 3 clinical development for this indication.
Betamethasone valerate is a corticosteroid that works by binding to glucocorticoid receptors in the skin, which modulates gene expression to reduce inflammation, itching, and redness. This mechanism helps manage the symptoms of atopic eczema by suppressing the local immune response and inflammatory mediators in affected skin areas.
Betamethasone valerate is being developed by Perrigo Company plc, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PRGO. Perrigo is conducting clinical research to evaluate the drug's safety and efficacy for treating atopic eczema.
Betamethasone valerate is in Phase 3 clinical development for atopic eczema. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the company is likely analyzing the results to determine next steps toward potential regulatory submission.
Betamethasone valerate has one completed Phase 3 clinical trial registered as NCT00576238, titled 'Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser.' This randomized, double-blind, active-controlled study enrolled 55 participants in Sweden and evaluated the drug's skin tolerance in adults aged 18 years and older.
Betamethasone valerate is a prodrug form of betamethasone, meaning it is a derivative that is converted into the active corticosteroid betamethasone in the body. While related, they are distinct chemical entities. Betamethasone valerate is specifically formulated for topical use to treat skin conditions like atopic eczema, offering improved skin penetration and local anti-inflammatory effects.